Cleveland Bio (CBLI) Gets Advce Letter from FDA for Entolimod as Radiation Countermeasure
Tweet Send to a Friend
Cleveland BioLabs, Inc. (Nasdaq: CBLI) announced the receipt of an Advice Letter from the U.S. Food and Drug Administration (FDA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
